The comparison between AML patients and healthy donors showed a significant decrease (p < 0.001) in the percentage of DNAM-1+ NK cells in AML patients (AML: 76.8 ± 20.4%; HD: 93.9 ± 5.9%) (Figure 1a). The gene discussed is CD226; the disease is acute myeloid leukemia.